Relaxation by cromakalim and pinacidil of isolated smooth muscle cells from canine coronary artery-multiple sites of action.
Dispersed cells were isolated from the canine coronary artery by enzymatic digestion. Their contraction and relaxation were determined by measuring their length using a video microscaler system. The cells remained structurally intact when examined by Trypan blue exclusion and electron microscopy. The cells showed a concentration-dependent contraction (EC50: 2.3 +/- 0.36 x 10(-12) M) to phenylephrine. The phenylephrine-induced contraction of the intact cells was inhibited by cromakalim (IC50: 1.24 +/- 0.27 x 10(-10) M) and pinacidil (IC50: 6.8 +/- 1.89 x 10(-10) M). The sensitivity of the dispersed cells to cromakalim was approximately 3 orders of magnitude larger than that of the muscle strips (EC50: 1.94 +/- 0.22 x 10(-7) M). Glibenclamide (a selective inhibitor of the ATP-sensitive K+ channel in pancreatic beta-cells) competitively antagonized the cromakalim-induced inhibition of the phenylephrine-contraction in intact cells (pA2:9.12; slope: 1.13) as well as in muscle strips (pA2: 7.84; slope: 0.95). Permeabilized cells were made by a brief exposure of the cells to saponin and were suspended in a buffer medium containing 100 mM KCl and 0.18 microM Ca++. The cells showed a concentration-dependent contraction to phenylephrine (EC50:2.2 +/- 0.40 x 10(-12) M) and inositol 1,4,5-triphosphate (EC50: 5.3 +/- 1.05 x 10(-11) M). These contractions were concentration-dependently inhibited by cromakalim and pinacidil. The inhibition by cromakalim of the inositol-induced contraction was markedly antagonized by apamin and, to a lesser extent, by glibenclamide. Thus, it is suggested that cromakalim and pinacidil exert a potent relaxation by acting on multiple sites: the glibenclamide-sensitive K+ channels of the plasma membrane and the intracellular site sensitive to inositol and apamin.
Rhim
B Y
BY
Department of Pharmacology, College of Medicine, Pusan National University, Korea.
Hong
K W
KW
D000818:Animals; D001030:Apamin / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002463:Cell Membrane Permeability / Q000187:drug effects; D002470:Cell Survival; D003331:Coronary Vessels / Q000187:drug effects* / Q000378:metabolism; D019806:Cromakalim; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D005905:Glyburide / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology*; D007294:Inositol / Q000494:pharmacology; D008297:Male; D008854:Microscopy, Electron; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects* / Q000648:ultrastructure; D010656:Phenylephrine / Q000494:pharmacology; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects; D011758:Pyrroles / Q000494:pharmacology*; D012503:Saponins / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*
D001578:Benzopyrans; D006146:Guanidines; D015221:Potassium Channels; D011758:Pyrroles; D012503:Saponins; D014665:Vasodilator Agents; D019806:Cromakalim; D010656:Phenylephrine; D001030:Apamin; D007294:Inositol; D020110:Pinacidil; D005905:Glyburide